Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America - sprookjes - yvandenbroek - TriplyDB

Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America

Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America

http://www.wikidata.org/entity/Q33853922

about

Differences in reversion of resistance mutations to wild-type under structured treatment interruption and related increase in replication capacity Predictors of Treatment Failure among Adult Antiretroviral Treatment (ART) Clients in Bale Zone Hospitals, South Eastern Ethiopia Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors.A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen.Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america.Assessing the performance of a computer-based policy model of HIV and AIDS Resistance evolution in HIV - modeling when to intervene.Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study.Retention in care among HIV-infected patients in resource-limited settings: emerging insights and new directions.Short communication: Transmitted drug resistance and molecular epidemiology in antiretroviral naive HIV type 1-infected patients in Rhode Island.The successful application of a national peer advisory committee for physicians who provide salvage regimens to heavily antiretroviral-experienced patients in mexican human immunodeficiency virus clinics Outwitting evolution: fighting drug-resistant TB, malaria, and HIV.Trends in Decline of Antiretroviral Resistance among ARV-Experienced Patients in the HIV Outpatient Study: 1999-2008 Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial HIV Viral Load Monitoring Frequency and Risk of Treatment Failure among Immunologically Stable HIV-Infected Patients Prescribed Combination Antiretroviral Therapy.HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.Risk factors for short-term virologic outcomes among HIV-infected patients undergoing regimen switch of combination antiretroviral therapy Efficacy of a clinical decision-support system in an HIV practice: a randomized trial.Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease.Socially-integrated transdisciplinary HIV prevention.Receipt and timing of HIV drug resistance testing in six U.S. jurisdictions.Virologic and immunologic effectiveness at 48 weeks of darunavir-ritonavir-based regimens in treatment-experienced persons living with HIV-1 infection in clinical practice: a multicenter Brazilian cohort.Enroling and retaining human immunodeficiency virus (HIV) patients in their care: A metasynthesis of qualitative studies Effectiveness of enfuvirtide in a cohort of highly antiretroviral-experienced HIV-1-infected patients in Mexico.Trends in prevalence of HIV-1 drug resistance in Thailand 2009-2010.Improving retention in HIV care among adolescents and adults in low- and middle-income countries: A systematic review of the literature.Use of InfCare HIV to identify and characterize suboptimally treated HIV patients at a Danish HIV clinic: a cross-sectional cohort study.Collaborative, pooled and harmonized study designs for epidemiologic research: challenges and opportunities.Induction of HIF-1α by HIV-1 Infection in CD4 T Cells Promotes Viral Replication and Drives Extracellular Vesicle-Mediated Inflammation

P2860

Q28477017-704013E7-8D4E-4C3D-8FF1-7B7799605C44 Q28554591-CCCD44E5-2FD9-4D52-B0A9-2F7FBD9C34C6 Q33876683-4151FBA2-4E62-491B-8BCE-0C4CB2679C28 Q33932293-DE594434-3F98-42E7-B069-99412BEF9C56 Q33981074-32DF0199-CB87-4269-A672-39439C753145 Q34115343-88DCA21B-A812-4E0B-B354-B02A8822329B Q34247013-DF202100-32D9-4A64-9713-2CC08C0D8DC5 Q34474961-C79E5F95-49BA-42D4-8681-FFFA1280D7D7 Q34495138-41E1973C-555B-4285-AE96-6DAC66F25035 Q34624825-1E3B91D3-5440-4857-ABB3-C5A86026FDA4 Q34802051-F8EC04DA-BEB2-436E-8964-B72A0E48B099 Q35878689-E3B10A17-3FD0-4707-8C65-7DD6E224DC2F Q35949742-E618C926-0082-4CD9-833D-CB7587BA1B1E Q36179320-8D5CA47B-AB18-4A4F-848B-BF1AAAB67B21 Q36311789-779DFF81-9630-4FE8-9F2C-3A9A04658EC1 Q36412256-800A7976-4F09-47E1-BA7F-73554D24D909 Q36419475-5B8B96E8-6B0D-47ED-8B90-E479EE49608F Q37313077-217EB60F-36AD-4213-976D-0BF16EDC6D6C Q37598398-432F65F2-1E4B-43E5-86C2-0D2B57CA7C9F Q37732465-AA0A98AD-BE7D-4AD9-80F3-DDB1BDB476D7 Q38808447-82108760-A5BA-46A0-9DFA-727CDB896F9C Q38910036-8C9A6579-B967-4116-94B6-DABFB1604308 Q38919590-82E4D304-CD38-4643-B310-E90C6B4B5EEE Q41567745-D20EDBA8-D87B-49B8-8E79-7064931AD089 Q42269396-E0723F06-4877-4A42-820F-3385029B34BE Q42367517-E52728F7-3B86-42DA-B675-4C2278884FA0 Q43734036-27DF3713-F407-404A-8FCD-B6D651C0A5F4 Q50041539-A5C4A34B-031B-4ABB-BBB2-2214B8F1C93F Q58751688-949ABAC4-B194-4B6E-8ECD-BCB3C951C94A

P2860

Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America

http://www.wikidata.org/entity/Q33853922

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Trends in multidrug treatment ...... HIV infection in North America

@ast

Trends in multidrug treatment ...... HIV infection in North America

@en

type

label

Trends in multidrug treatment ...... HIV infection in North America

@ast

Trends in multidrug treatment ...... HIV infection in North America

@en

prefLabel

Trends in multidrug treatment ...... HIV infection in North America

@ast

Trends in multidrug treatment ...... HIV infection in North America

@en

P1433

Q33853922-E87187CF-D04E-4493-AECE-EE845A133841

P1476

Q33853922-38C9AD04-CA15-482C-836E-FBDA66DAFA16

P2093

Q33853922-003AA408-438A-476A-9E2B-85A2D544F5C9

Q33853922-3D32A455-59A8-447B-B1BC-B16E8DF3D71A

Q33853922-4F676C0E-D789-48E1-B6A1-042BE1C925FD

Q33853922-60BF745C-5027-410D-9B06-CBA945F031AF

Q33853922-6CCD527B-5D6F-4238-96E3-2453FDF2F36E

Q33853922-733F3DFD-863B-424F-84A7-167EFA038775

Q33853922-769E0D4A-D6B7-4F5E-81AD-C2B4B07A709F

Q33853922-7895D0BC-12D1-4F7E-A240-F0B80EB72FCE

Q33853922-7FE4849E-A984-420A-9FB4-04CE7645B8E4

Q33853922-88BCA687-CDDD-4E3E-8B17-6D0D84BE52EA

P2860

Q33853922-02F77A8D-445E-4EAD-8D7D-E99295A1A14A

Q33853922-063B1851-F7DC-4C78-9E02-8411BFF8AD87

Q33853922-1FB025B9-327C-43AF-84C3-F660B9CA2CA4

Q33853922-2386EBF5-D387-4422-98B3-CEFC136B876A

Q33853922-4C387575-1086-459C-B36E-2AD7951C49E8

Q33853922-4E22F0C0-6426-4C91-A384-49D3893A08F3

Q33853922-53929C8D-8735-439B-AAC8-6F19B16562BF

Q33853922-55DD9B96-3576-4026-8FEA-6686315C9180

Q33853922-7DDC27D6-1EAB-4D25-97ED-10CEF84BAFE1

Q33853922-801F99AE-8DCC-41DE-B85E-72799EE3C5D6

P304

Q33853922-AE5D6068-C1F7-4EFF-97DA-270FB6F10D39

P31

Q33853922-000EAF26-9760-4EE4-B28C-D4D61C8DEA6A

P356

Q33853922-DF83F001-395D-410B-9389-A502C741BB6D

P407

Q33853922-48A1E0B1-9D3B-4B50-8895-852915C208F9

P433

Q33853922-218DC44E-33BB-4A8D-91A2-0360E93E9CA3

P478

Q33853922-924B2EC1-F51B-4D43-96F8-74F1CC1A2742

P50

Q33853922-14B64BED-EB83-40A6-8E96-4EB731AB89C1

Q33853922-18D8C0CE-9611-4E05-8B0A-149A7CA9A3D1

Q33853922-3EADF61C-9718-4E8D-AEBB-D7BBDA822C89

Q33853922-4CD89228-7D56-49D5-A5FE-917714E4F49E

Q33853922-55374C89-D98B-465A-A3C5-B42A2F4090E4

Q33853922-9497F5D4-4C12-44AA-AFA3-A2A8A7E1AC8F

Q33853922-DF88F4F2-C52B-489D-8CED-466645F9B23C

Q33853922-E8E56575-F7A1-48C0-8697-296174520A3C

P577

Q33853922-87EED33E-8D6F-40C9-884D-FA21D9E692D5

P5875

Q33853922-110452BE-258B-42DF-8688-A7F4E1B4F4D5

P698

Q33853922-E5F1C011-A35D-4052-B8F5-5ED16A9ABAAD

P921

Q33853922-00C743E9-10AE-463C-AB7F-B69E29483DFC

P932

Q33853922-4C34AF35-EA39-4303-B2C3-8DF9C27C1B21

P356

P1433

Clinical Infectious Diseases

P1476

Trends in multidrug treatment ...... HIV infection in North America

@en

P2093

Amy C Justice

http://www.w3.org/2001/XMLSchema#string

Anita R Rachlis

http://www.w3.org/2001/XMLSchema#string

Ann C Collier

http://www.w3.org/2001/XMLSchema#string

Constance A Benson

http://www.w3.org/2001/XMLSchema#string

Gregory D Kirk

http://www.w3.org/2001/XMLSchema#string

James J Goedert

http://www.w3.org/2001/XMLSchema#string

Jeffrey N Martin

http://www.w3.org/2001/XMLSchema#string

John T Brooks

http://www.w3.org/2001/XMLSchema#string

Kelly A Gebo

http://www.w3.org/2001/XMLSchema#string

Lisa P Jacobson

http://www.w3.org/2001/XMLSchema#string

P2860

Raltegravir with optimized background therapy for resistant HIV-1 infection

Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).

Effect of early versus deferred antiretroviral therapy for HIV on survival.

HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis.

Maraviroc for previously treated patients with R5 HIV-1 infection

Treatment of antiretroviral-drug-resistant HIV-1 infection.

Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 Cells/mm3.

Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure.

What is the risk of mortality following diagnosis of multidrug-resistant HIV-1?

Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group.

P304

1582-1590

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/644768

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

Benigno Rodriguez

Margot B Kushel

Michael John Gill

Sonia Napravnik

P577

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38026400

http://www.w3.org/2001/XMLSchema#string

P698

19845473

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

2871149

http://www.w3.org/2001/XMLSchema#string